Skip to main content

Biodegradable Self-Assembled MPEG-PCL Micelles for Hydrophobic Oridonin Delivery In Vitro

Buy Article:

$113.00 plus tax (Refund Policy)

Abstract:

The great potential of oridonin (ORI) for clinical application in cancer therapy is greatly limited due to its poor water-solubility. The purpose of this study was to increase the water solubility of oridonin using monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (MPEG-PCL) as drug carrier. The ORI-loaded MPEG-PCL micelles were prepared by thin film hydration method. The obtained ORI-micelles could be lyophilized into powder form, which could be re-dissolved in water to form homogeneous solution. This study showed that ORI was successfully incorporated in the core–shell structure of MPEG-PCL micelles and maintained its anticancer activity. The average particle size was 25.55±0.10 nm and the mean zeta potential was −4.71±0.05 mV. The actual drug loading and encapsulation efficiency were 7.99±0.03% and 99.51±0.34%, respectively. ORI could be released from MPEG-PCL micelles in a sustained manner in vitro. The permeation profiles of ORI from ORI-micelles and ORI water saturated solution through excised mouse skin demonstrated that ORI-micelles showed much better transdermal penetration performance than ORI water saturated solution. The prepared ORI-micelles have great potential for both direct intravascular administration and being further developed as a transdermal drug delivery system in cancer chemotherapy.

Keywords: MICELLES; MPEG-PCL; ORIDONIN; SELF-ASSEMBLY; TRANSDERMAL DRUG DELIVERY

Document Type: Research Article

DOI: http://dx.doi.org/10.1166/jbn.2012.1358

Publication date: February 1, 2012

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
asp/jbn/2012/00000008/00000001/art00008
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more